Quality of life assessment following peptide receptor radionuclide therapy (PRRT) of pancreatic neuroendocrine tumor (P-NET)

被引：0
|
作者：
Marinova, Milka [3 ]
Muecke, Martin [1 ]
Mahlberg, Lukas [2 ]
Essler, Markus [2 ]
Cuhls, Henning [1 ]
Radbruch, Lukas [1 ]
Ahmadzadehfar, Hojjat [2 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
[2] Univ Hosp Bonn, Nucl Med, Bonn, Germany
[3] Univ Hosp Bonn, Radiol, Bonn, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1462
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)
    Ladwa, R.
    Pattison, D.
    Smith, J.
    Goodman, S.
    Burge, M.
    Rose, S.
    Dowson, N.
    Wyld, D.
    NEUROENDOCRINOLOGY, 2018, 106 : 249 - 249
  • [22] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
    Bodei, L.
    Pepe, G.
    Paganelli, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
  • [23] Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
    Miotto, M.
    Nessi, C.
    Cingarlini, S.
    Severi, S.
    Paganelli, G.
    Malleo, G.
    D'Onofrio, M.
    Pea, A.
    Vincenzi, S.
    Scarpa, A.
    Salvia, R.
    Landoni, L.
    NEUROENDOCRINOLOGY, 2019, 108 : 254 - 254
  • [24] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Marco Schiavo Lena
    Stefano Partelli
    Paola Castelli
    Valentina Andreasi
    Chanel Elisha Smart
    Eleonora Pisa
    Mirco Bartolomei
    Emilio Bertani
    Giuseppe Zamboni
    Massimo Falconi
    Claudio Doglioni
    Endocrine Pathology, 2020, 31 : 119 - 131
  • [25] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Schiavo Lena, Marco
    Partelli, Stefano
    Castelli, Paola
    Andreasi, Valentina
    Smart, Chanel Elisha
    Pisa, Eleonora
    Bartolomei, Mirco
    Bertani, Emilio
    Zamboni, Giuseppe
    Falconi, Massimo
    Doglioni, Claudio
    ENDOCRINE PATHOLOGY, 2020, 31 (02) : 119 - 131
  • [26] TUMOR RESPONSE TO PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN A UNITED STATES-BASED NEUROENDOCRINE TUMOR COHORT
    Kipnis, Sarit T.
    Hung, Matthew
    Heckert, Jason
    Bennett, Bonita J.
    Creamer, Caroline
    Eads, Jennifer
    Soulen, Michael C.
    Pryma, Daniel
    Mankoff, David
    Metz, David C.
    Katona, Bryson W.
    GASTROENTEROLOGY, 2020, 158 (06) : S292 - S292
  • [27] INITIAL EXPERIENCE WITH PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) FOR THE TREATMENT OF NEUROENDOCRINE TUMOR (NET) AT A TERTIARY CARE UNITED STATES CENTER.
    Heckert, Jason
    Eads, Jennifer
    Soulen, Michael C.
    Pryma, Daniel
    Mankoff, David
    Metz, David C.
    Katona, Bryson W.
    GASTROENTEROLOGY, 2019, 156 (06) : S370 - S370
  • [28] Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours
    Alsadik, Shahad
    Yusuf, Siraj
    AL-Nahhas, Adil
    CURRENT RADIOPHARMACEUTICALS, 2019, 12 (02) : 126 - 134
  • [29] Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience
    Duan, Heying
    Ninatti, Gaia
    Girod, Bradley
    Ferri, Valentina
    Guja, Kip
    Song, Hong
    Kunz, Pamela
    Fisher, George
    Iagaru, Andrei
    Aparici, Carina Mari
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [30] Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors
    Alayli, Adam
    Ngo, Hoang
    Sikaria, Dhiraj
    Ahmed, Altan
    Salloum, Elias
    Strosberg, Jonathan R.
    Al-Toubah, Taymeyah E.
    Kis, Bela
    Haider, Mintallah
    El-Haddad, Ghassan
    CANCERS, 2024, 16 (15)
12345